Daratumumab With Len-Dex Prolongs PFS in R/R Multiple Myeloma

Share this content:
A patient undergoes regular chemotherapy.
A patient undergoes regular chemotherapy.

Adding daratumumab to lenalidomide and dexamethasone significantly prolonged progression-free survival compared with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma, a study published in The New England Journal of Medicine has shown.1

Because this daratumumab in combination with lenalidomide and dexamethasone demonstrated promising activity in a phase 1/2 trial, researchers sought to evaluate the efficacy and safety of the combination in a phase 3 trial.

For the open-label, POLLUX study (A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma; ClinicalTrials.gov Identifier: NCT02076009), investigators enrolled 569 patients with multiple myeloma who had received at least 1 prior line of therapy. Participants were randomly assigned to receive lenalidomide and dexamethasone with or without daratumumab.

At a median follow-up of 13.5 months, results showed that treatment with daratumumab was associated with 63% reduction in the risk of progression or death compared with lenalidomide plus dexamethasone alone (hazard ratio [HR], 0.37; 95% CI, 0.27-0.52; P <.001). The 12-month progression-free survival rates were 83.2% (95% CI, 78.3-87.2) in the daratumumab group vs 60.1% (95% CI, 54.0-65.7) in the control arm.

Researchers also found that significantly more daratumumab-treated patients achieved an overall response and a complete response or better (P <.001).

The most common grade 3 to 4 treatment-related adverse events in the daratumumab arm were neutropenia, thrombocytopenia, anemia. Daratumumab was associated with a higher rate of neutropenia vs the control arm.

Of note, nearly half of patients who received daratumumab experienced infusion-related reactions, which were mostly of grade 1 to 2 severity.


1. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319-1331.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs